Delivers strong Q2 results and raises FY26 revenue growth, margin expansion, and non-GAAP EPS(4) guidance on continued operational momentum Second-quarter fiscal year 2026 Revenue of $1.83 billion for the second quarter ended April 30, 2026, ... Read more
From advanced biologics and cell therapies to increasingly stringent regulatory expectations, today’s pharmaceutical manufacturing environments demand far more than traditional cleanroom infrastructure. Facilities must now deliver operational... Read more
As biologics, advanced therapies, and specialised injectable medicines continue to reshape the pharmaceutical landscape, the demand for agile and highly compliant sterile manufacturing partners has never been greater. In this Biopharma Boardr... Read more
As clinical development grows more complex and globally interconnected, biotech companies are under increasing pressure to build CRO partnerships that deliver more than operational support. In this Biopharma Boardroom Q&A, Greg Plunkett discusses... Read more
Q1 2026 Group performance Comparable order intake growth 6% Group sales of EUR 3.9 billion, reflecting 4% increase in comparable sales Income from operations increased to EUR 241 million Adjusted EBITA margin increased 40 basis points t... Read more
Financial performance Q1 2026 reported sales increased by 32% at CER, positively impacted by a provision reversal related to the 340B Drug Pricing Program in the US. Q1 2026 adjusted sales, excluding the 340B provision reversal, decreased... Read more
AGC Biologics, your friendly CDMO expert, was selected by Teikoku Seiyaku Co., Ltd., a leader in transdermal drug delivery, to provide microbial contract development and manufacturing services for KTP-001, a recombinant human matrix metalloproteina... Read more
LOTTE Biologics (Co-CEOs James Park and Yooyeol Shin) announce an expansion of its collaboration with Ottimo Pharma, an innovative biotech company developing one-of-a-kind PD-1/VEGFR2 dual-paratopic antibodies, reinforcing a growing strategic ... Read more
© 2026 Biopharma Boardroom. All Rights Reserved.
